{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":10,"youtube":7,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04919811\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TRUST-II","nct_id":"NCT04919811","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trust-ii-nct04919811. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TRUST-II","arms":[{"description":"Single-arm trial whereby all consented, enrolled, eligible patients receive taletrectinib","label":"Taletrectinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":217,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Taletrectinib","type":"DRUG"}],"last_update":"2026-01-07","lead_sponsor":"Nuvation Bio Inc.","official_title":"A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-06-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective response rate (ORR) by independent radiology review committee (IRC)","timeFrame":"Up to 4 years"}],"references":[{"citation":"Perol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025 Jun;43(16):1920-1929. doi: 10.1200/JCO-25-00275. Epub 2025 Apr 3.","pmid":"40179330","type":"DERIVED"},{"citation":"Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Perol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. Future Oncol. 2023 Jan;19(2):123-135. doi: 10.2217/fon-2022-1059. Epub 2023 Mar 6.","pmid":"36877099","type":"DERIVED"}],"start_date":{"date":"2021-09-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","url":"https://clinicaltrials.gov/study/NCT04919811"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trust-ii-nct04919811"}